Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Mycobacterium tuberculosis Beijing Lineage and Risk for Tuberculosis in Child Household Contacts, Peru

Chuan-Chin Huang1, Alexander L. Chu1, Mercedes C. Becerra, Jerome T. Galea, Roger Calderón, Carmen Contreras, Rosa Yataco, Zibiao Zhang, Leonid Lecca, and Megan B. MurrayComments to Author 
Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (C.-C. Huang, M.C. Becerra, Z. Zhang, M.B. Murray); Harvard Medical School, Boston (C.-C. Huang, M.C. Becerra, M.B. Murray); Harvard University Division of Continuing Education, Cambridge, Massachusetts, USA (A.L. Chu); University of South Florida, Tampa, Florida, USA (J.T. Galea); Socios En Salud Sucursal, Lima, Peru (R. Calderon, C. Contreras, R. Yataco, L. Lecca)

Main Article

Table 7

Effects of BCG vaccination on M. tuberculosis infection and TB outcomes by lineage exposure for child and adult household contacts of culture-positive pulmonary tuberculosis patients, Lima, Peru, September 2009–August 2012*

Category and BCG vaccination status
 Non-Beijing lineage
Beijing lineage
 p value
Infection prevalence, no. (%)
 RR (95% CI)
 Infection prevalence, no. (%)
 RR (95% CI)
Children, <15 y
Baseline M. tuberculosis infection, n = 2,949
0.691
Without BCG vaccination
 137 (27)
 Referent
19 (32)
 Referent
With BCG vaccination
 552 (26)
 0.94 (0.81–1.09)
  
 83 (32)
 1.01 (0.69–1.49)
M. tuberculosis infection by 12 months of follow-up, n = 2,417
0.405
Without BCG vaccination
 187 (45)
 Referent
26 (50)
 Referent
With BCG vaccination 853 (50)
 1.07 (0.97–1.19)
139 (60)
 1.21 (0.90–1.63)
Incidence†
 HR (95% CI)
Incidence†
 HR (95% CI)
Time to TST conversion
0.579
Without BCG vaccination
 0.18 (48/260)
 Referent
0.21 (7/32)
 Referent
With BCG vaccination
 0.27 (292/1,065)
 1.5 (1.08–2.08)
0.45 (53/119)
 1.84 (0.77–4.39)
Time to TB
0.168
Without BCG vaccination
 4,585 (25/545)
 Referent
3,098 (2/65)
 Referent
With BCG vaccination 2,619 (60/2291)
 0.58 (0.35–0.96)
4,639 (13/280)
 1.96 (0.41–9.39)
Infection prevalence, no. (%)
 RR (95% CI)
Infection prevalence, no. (%)
 RR (95% CI)
Adults, >15 y
Baseline M. tuberculosis infection, n = 5,381
0.611
Without BCG vaccination
 260 (47)
 Referent
27 (51)
 Referent
With BCG vaccination
 2,263 (54)
 1.07 (0.98–1.18)
313 (54)
 1.00 (0.78–1.29)
M. tuberculosis infection by 12 months of follow-up, n = 4,716
0.315
Without BCG vaccination
 334 (72)
 Referent
39 (81)
 Referent
With BCG vaccination 3,042 (82)
 1.10 (1.04–1.16)
419 (82)
 1.02 (0.89–1.16)
Incidence†
 HR (95% CI)
Incidence†
 HR (95% CI)
Time to TST conversion 0.315
Without BCG vaccination 0.41 (70/172) Referent 0.77 (10/13) Referent
With BCG vaccination 0.72 (728/1,020) 1.55 (1.18–2.04) 0.73 (105/144) 1.00 (0.48–2.06)
Time to TB 0.732
Without BCG vaccination 4,813 (28/582) Referent 6,574 (4/61) Referent
With BCG vaccination 2,860 (129/4511) 0.66 (0.43–1.02) 2,434 (15/616) 0.53 (0.17–1.68)

*BCG, M. bovis BCG; HR, hazard ratio; RR, risk ratio; TB, tuberculosis; TST, tuberculin skin test.
†Cases per person-year (no. converted/no. tested).

Main Article

1These authors contributed equally to this article.

Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external